PORT WASHINGTON, N.Y., Nov. 02, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), focused on the global marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the first quarter of fiscal 2018 ended September 30, 2017.
First Quarter Fiscal 2018 versus First Quarter Fiscal 2017
- Net sales of $185.3 million versus $128.0 million, a 44.7% increase
- Gross profit of $40.0 million versus $30.8 million, a 29.7% increase
- Net income of $0.5 million versus $4.4 million, a 89.6% decrease
- Diluted EPS of $0.01 versus $0.15, an 93.3% decrease
- Non-GAAP Adjusted Net Income of $10.7 million versus $8.3 million, a 29.1% increase
- Non-GAAP Adjusted EPS of $0.30 versus $0.28, a 7.1% increase
“Our legacy Rising Pharmaceuticals business posted its first year-over-year increase in quarterly sales in over a year, supported by new product launches in the second half of fiscal 2017. In addition, Human Health segment sales benefited from the addition of the Citron and Lucid products. However, pricing pressure on the more mature products in the legacy Rising portfolio and the inclusion of the Citron and Lucid products, which carry a lower gross margin, contributed to a contraction in segment profitability,” said William C. Kennally, III, Chief Executive Officer of ACETO. “On the strength of the cash flow generated by our stable Pharmaceutical Ingredients and Performance Chemicals segments and a significant improvement in our Human Health accounts receivable collections, we generated $44 million in operating cash flow, which gave us ample funds to pay down $24 million of long-term debt for a leverage ratio of 3.71x at quarter end.
“While our first quarter results were largely in-line with our expectations and we still plan to launch 15 to 20 products in fiscal 2018, the timing of some of our product launches will be delayed due to API constraints and technical challenges, issues which we expect to fully resolve as the year progresses. Additionally, our current view of industry conditions is now indicating greater than previously expected headwinds in terms of both competitive intensity and the impact from ongoing customer consolidations. As a result, we are lowering our net sales and profit guidance. Nevertheless, we believe we remain well positioned to weather what has become a prolonged generics industry downturn and grow net sales, based on the steady supply of new products to launch, our strong balance sheet and our steady cash generating businesses. With our large and diversified portfolio of 140 generic drug products and robust pipeline of 115 product candidates, consisting of 60 ANDAs approved or on file at the FDA and 55 products under development, our strategic transition toward human health will continue to move forward,” concluded Mr. Kennally.
Please see fiscal 2018 guidance provided within this press release after the financial review.
First Quarter Financial Review
Net sales for the first quarter of fiscal 2018 were $185.3 million, an increase of 44.7% from $128.0 million reported in the first quarter of fiscal 2017. Total Company gross profit was $40.0 million, an increase of 29.7%, compared to $30.8 million in the first quarter of fiscal 2017. Gross margin for the first quarter was 21.6% compared to 24.1% in the prior year period.
Human Health segment sales were $106.0 million, an increase of 121.4%, compared to $47.9 million for the first quarter of fiscal 2017. The revenue increase primarily reflects the addition of $55.1 million from the acquisition of certain products and related assets of Citron and Lucid. Gross profit for the Human Health segment was $24.6 million, an increase of 73.5%, compared to $14.2 million for the first quarter of fiscal 2017, reflecting the addition of certain products and related assets of Citron and Lucid. Gross margin for the first quarter was 23.2%, compared to 29.7% in the prior year period. The decrease in gross margin was due to the addition of relatively lower gross margin from the Citron and Lucid products and to the decline of gross profit for certain legacy Rising products.
Pharmaceutical Ingredients segment sales were $36.6 million, a decrease of 9.9%, compared to $40.6 million for the first quarter of fiscal 2017. The segment’s sales decrease was driven by lower sales of domestic APIs. Gross profit in the quarter was $5.8 million, a 16.0% decrease compared to $7.0 million for the first quarter of fiscal 2017. Gross margin for the first quarter was 16.0%, compared to 17.1% in the prior year period. The decrease in gross profit and margin was driven by lower sales of domestic APIs and a less favorable product mix in APIs.
Performance Chemicals segment sales were $42.7 million, an increase of 8.0% compared to $39.5 million for the first quarter of fiscal 2017, largely due to higher sales of agricultural and pigment intermediates in the Specialty Chemicals business. Gross profit was $9.5 million, a decrease of 1.9%, compared to $9.7 million for the first quarter of fiscal 2017. Gross margin was 22.3% for the first quarter, compared to 24.5% in the prior year period. The decrease in gross profit and margin was primarily due to lower sales of certain agricultural protection products and a less favorable product mix of specialty chemical products.
Total selling, general and administrative expenses were $31.1 million compared to $21.0 million in the same period last year, a 48.2% increase, with $5.4 million of the increase attributable to amortization expense associated with the purchase of intangible assets related to the Citron and Lucid product purchase. Also included in selling, general and administrative expenses for the first quarter of 2018 were $4.1 million of one-time costs associated with the departure of the company’s former CEO. Research and Development expenses in the first quarter totaled $1.6 million compared to $1.1 million in the prior year period. The majority of R&D expenses are milestone based and fluctuate quarterly.
Operating income totaled $7.2 million, a decrease of 17.6% from the first quarter of fiscal 2017. Net income was $0.5 million, or $0.01 per diluted share, compared to net income of $4.4 million, or $0.15 per diluted share, for the comparable quarter of fiscal 2017. Non-GAAP Adjusted Net Income was $10.7 million in the first quarter, compared to $8.3 million in the prior period, a 29.1% increase. Non-GAAP Adjusted Earnings per Share were $0.30, compared to $0.28 in the year ago first quarter, a 7.1% increase.
Fiscal 2018 Guidance
For the fiscal year ending June 30, 2018, at current exchange rates, ACETO is providing financial guidance as follows:
- Total revenues to increase approximately 15% to 20%;
- Reported diluted GAAP earnings per share between $0.23 and $0.33;
- Diluted Non-GAAP earnings per share between $1.05 and $1.15.
The Company's fiscal 2018 financial guidance is based in part on the following assumptions:
- Generic industry headwinds continued in our first fiscal quarter and we are expecting annual price erosion in the low double digits percentage;
- R&D expense of approximately $10 million; and
- Total generic product launches of 15 to 20.
Senior Financial Executive Changes
On October 26, 2017, Doug Roth, Senior Vice President and Chief Financial Officer of ACETO, announced his retirement from the company, effective March 31, 2018. The company has commenced a search for his replacement. Also, on October 27, 2017, Fran Scally, ACETO Vice President, Financial Reporting, Compliance and Risk, was designated to serve as the company’s chief accounting officer, effective immediately.
Management will host a conference call to discuss the operating and financial results at 9:00 a.m. ET on Friday, November 3, 2017. To participate in the conference call, please dial (877) 317-6789 or (412) 317-6789 approximately 10 minutes prior to the call. Please reference conference ID # 10112224.
The call is also being webcast with an accompanying presentation, which can be accessed through the investor relations section of the Company’s website, www.aceto.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software and download the presentation.
A telephone replay of the conference call will be available from 11:00 a.m. ET on November 3, 2017 until 11:59 p.m. ET on November 10, 2017 and may be accessed by calling (877) 344-7529 and referencing conference ID # 10112224. An archived replay of the conference call will also be available in the investor relations section of the Company’s website.
Use of Non-GAAP Financial Information
In addition to U.S. GAAP results, this press release also includes certain non-GAAP financial measures as defined by the SEC. These measures, Adjusted Net Income and Adjusted EPS, are based upon net income excluding amortization of intangibles, debt extinguishment, amortization of debt discount and debt issuance costs, transaction costs related to acquisitions and the impact of Accounting Standards Update (“ASU”) 2016-09. These items should not be reviewed in isolation or considered substitutes of the Company’s financial results as reported in accordance with GAAP. Due to the nature of these items, it is important to identify these items and to review them in conjunction with the Company’s financial results reported in accordance with GAAP. The exclusion of these items also allows investors to compare results of operations in the current period to prior periods’ results based on the Company’s fundamental business performance and analyze the operating trends of the business. The exclusion of these items also allows management to evaluate the performance of its business units.
Pursuant to the requirements of Regulation G, reconciliations of Adjusted Net Income and Adjusted EPS to U.S. GAAP net income and GAAP EPS are presented in the table Non-GAAP Reconciliation of this press release.
ACETO Corporation, incorporated in 1947, is focused on the global marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). With business operations in nine countries, ACETO distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. ACETO's global operations, including a staff of 25 in China and 12 in India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.
This news release contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this news release may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of ACETO’s plans or strategies, financing plans, projected or anticipated benefits from acquisitions that ACETO may make including the recently announced acquisition of products from Citron Pharma, LLC, or a projection involving anticipated revenues, earnings or other aspects of ACETO’s operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. ACETO intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release include, but are not limited to, the Company’s sales and earnings guidance and statements regarding the expected impact of product launches. ACETO cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond ACETO’s control, which may influence the accuracy of the statements and the projections upon which the statements are based. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO’s reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 and other filings. Copies of these filings are available at www.sec.gov.
Any one or more of these uncertainties, risks and other influences could materially affect ACETO’s results of operations and whether forward-looking statements made by ACETO ultimately prove to be accurate. In addition, periodic high-margin product sales may have a positive material financial impact in a given quarter that may be non-recurring in future quarters, thereby rendering one quarter's performance not useful as a predictor of future quarters' results. ACETO’s actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
Investor Relations Contact:
(Financial Tables Follow)
|Aceto Corporation and Subsidiaries|
|Consolidated Statements of Income|
|(in thousands, except per share amounts)|
|Three Months Ended|
|Cost of sales||145,272||97,179|
|Gross profit %||21.6||%||24.1||%|
|Selling, general and|
|Research and development expenses||1,615||1,050|
|Other expense, net of interest expense||(5,081||)||(1,985||)|
|Income before income taxes||2,138||6,780|
|Income tax provision||1,684||2,395|
|Net income per common share||$||0.01||$||0.15|
|Diluted net income per common share||$||0.01||$||0.15|
|Weighted average shares outstanding:|
|Aceto Corporation and Subsidiaries|
|Consolidated Balance Sheets|
|(in thousands, except per-share amounts)|
|September 30, |
|June 30, |
|Cash and cash equivalents||$||72,100||$||55,680|
|Trade receivables: less allowance for doubtful|
|accounts: September 30, 2017 $476; and June 30, 2017 $485||240,620||260,889|
|Prepaid expenses and other current assets||4,916||3,941|
|Deferred income tax asset, net||-||546|
|Total current assets||467,700||471,555|
|Property and equipment, net||11,569||10,428|
|Property held for sale||6,250||7,152|
|Intangible assets, net||277,247||285,081|
|Deferred income tax asset, net||10,991||19,453|
|Liabilities and Shareholders' Equity|
|Current portion of long-term debt||$||14,482||$||14,466|
|Total current liabilities||227,149||222,805|
|Long-term debt, net||317,097||339,200|
|Environmental remediation liability||1,754||2,339|
|Deferred income tax liability||-||7,325|
|Commitments and contingencies|
|Preferred stock, 2,000 shares authorized; no shares issued and outstanding||-||-|
|Common stock, $.01 par value:|
|(75,000 shares authorized; 30,581 and 30,094 shares issued|
|and outstanding at September 30, 2017 and June 30, 2017, respectively)||306||301|
|Capital in excess of par value||217,439||214,198|
|Accumulated other comprehensive loss||(2,686||)||(5,112||)|
|Total shareholders' equity||409,230||405,067|
|Total liabilities and shareholders' equity||$||1,017,973||$||1,038,185|
|Diluted Net Income Per Common Share Excluding Charges (Non-GAAP Reconciliation)|
|(in thousands, except per share amounts)|
|Net income, as reported||$||454||$||0.01||$||4,385||$||0.15|
|Amortization of intangible assets||7,929||0.22||2,791||0.09|
|Transaction costs related to acquisitions||-||-||1,809||0.06|
|Amortization of debt discount (non-cash interest expense)||1,304||0.04||1,223||0.04|
|Amortization of debt issuance costs||209||0.01||209||0.01|
|Amortization of deferred financing costs||270||0.01||-||-|
|Adjusted income excluding charges||15,132||0.43||10,587||0.36|
|Adjustments to provision for income taxes including impact of ASU 2016-09||4,450||0.13||2,310||0.08|
|Adjusted net income (Non-GAAP)||$||10,682||$||0.30||$||8,277||$||0.28|
|Diluted weighted average shares outstanding||35,259||35,259||29,840||29,840|
|NOTE: Items identified in the above table are not in accordance with, or an alternative method for, generally accepted accounting principles (GAAP) in the United States. These items should not be reviewed in isolation or considered substitutes of the Company's financial results as reported in accordance with GAAP. Due to the nature of these items, it is important to identify these items and to review them in conjunction with the Company's financial results reported in accordance with GAAP. The exclusion of these items also allows investors to compare results of operations in the current period to prior period’s results based on the Company’s fundamental business performance and analyze the operating trends of the business. The exclusion of these items also allows management to evaluate performance of its business units. The Company does not provide reconciliations of GAAP and non-GAAP projections as such projections are intended for directional purposes only.|